MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2016 International Congress

    Taking specialist clinics into community nursing homes

    T. Williams, S. Mahon, C. Thomas, B. Mohamed (Cardiff, United Kingdom)

    Objective: Evaluate the effectiveness of delivering specialist Parkinson's care in community care home settings. Background: Our drive to improve older people's care has led to…
  • 2016 International Congress

    Medication use patterns vary across expert Parkinson’s disease clinics

    P. Schmidt, F. Cubillos, T. Simuni, C. Marras, T. Davis, E.C. Nelson (Miami, FL, USA)

    Objective: This analysis aims to describe and quantify the medication patterns for patients with Parkinson's disease (PD) managed in expert clinics. Background: Antiparkinson medication use…
  • 2016 International Congress

    Safety and tolerability of inhaled levodopa (CVT-301) administered to Parkinson’s disease patients with motor fluctuations

    R. Pahwa, P. LeWitt, A. Corbin, R. Batycky, H. Murck (Kansas City, KS, USA)

    Objective: Two Phase 2 studies were conducted to evaluate the safety profile of inhaled CVT-301 administered to Parkinson's disease (PD) patients with motor fluctuations. Background:…
  • 2016 International Congress

    Status of NPF-QII after six years: Updates to the dataset

    F. Cubillos, E.C. Nelson, T. Simuni, C. Marras, M. Rafferty, T. Davis, P. Schmidt (Miami, FL, USA)

    Objective: To describe the status and recent findings from the National Parkinson Foundation's Quality Improvement Initiative (NPF-QII), an 8,179 subject observational clinical study conducted at…
  • 2016 International Congress

    Clinical effect and dose conversion of rytary (numient) in 50 consecutive patients with PD motor fluctuations

    N. Chhabria, S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To review the clinical use of a newer extended-release levodopa preparation in 50 consecutive patients with PD experiencing motor fluctuations on immediate-release levodopa. Background:…
  • 2016 International Congress

    Evaluation of droxidopa dosing and clinical response in 50 consecutive patients with Parkinson’s disease and symptomatic neurogenic orthostatic hypotension

    S.H. Isaacson, S. Brillman, N. Chhabria (Boca Raton, FL, USA)

    Objective: To determine the effect of droxidopa on clinical symptoms and standing systolic blood pressure in patients with Parkinson's disease (PD) and neurogenic orthostatic hypotention…
  • 2016 International Congress

    Efficacy of apomorphine subcutaneous injections in patients with levodopa dose failures and morning akinesia

    S.H. Isaacson (Boca Raton, FL, USA)

    Objective: To assess the effect of subcutaneous injection of apomorphine (APO) in patients with Parkinson's disease (PD)and morning akinesia who experience dose failures after their…
  • 2016 International Congress

    Improvement in posture, pain, and cardiac autonomic function in a prospective study of osteopathic manipulative medicine and physical therapy for camptocormia in Parkinson’s disease

    J.D. Mancini, D.M. Pasternack, N. Caruana, A. Leder (Old Westbury, NY, USA)

    Objective: A prospective cohort study of the effectiveness of osteopathic manipulative medicine (OMM) and physical therapy in improving postural control and dysautonomia in Parkinson's disease…
  • 2016 International Congress

    When is the worst period of nocturnal hypokinesia in Parkinson’s disease? A sensor-based analysis

    J. Sringean, P. Taechalertpaisarn, C. Thanawattano, R. Bhidayasiri (Nonthaburi, Thailand)

    Objective: To quantify the number of turning in bed throughout the night as a determinant of the severity of nocturnal hypokinesia. Background: Nocturnal hypokinesia or…
  • 2016 International Congress

    The Parkinson progression marker initiative (PPMI) – Developing a comprehensive longitudinal biomarker dataset

    Parkinson Progression Marker Initiative (New Haven, CT, USA)

    Objective: The goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical, imaging and biospecimen biomarkers of PD progression to provide tools for…
  • « Previous Page
  • 1
  • …
  • 1544
  • 1545
  • 1546
  • 1547
  • 1548
  • …
  • 1554
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Insulin dependent diabetes and hand tremor
  • Improvement in hand tremor following carpal tunnel release surgery
  • Impact of expiratory muscle strength training (EMST) on phonatory performance in Parkinson's patients
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley